Compare DexCom, Inc. (DXCM) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Ralph Lauren Corp — how do they compare? DexCom, Inc. trades at $88.22 (market cap $33.08B), while Ralph Lauren Corp trades at $397.75 (market cap $24.24B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Ralph Lauren Corp pays a 0.92% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | RL | |
|---|---|---|
Market Cap | $33.08B | $24.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $414.25 |
52-Week Low | $54.84 | $285.35 |
Enterprise Value | $32.53B | $25.31B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Ralph Lauren (RL) trades at $395.53, down 0.08% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q1 2027 EPS of $4.59 exceeding expectations of $4.32, driven by robust demand and margin expansion. Revenue growth accelerated to 13% in constant currency, and the company updated its fiscal 2027 outlook upward. Key support lies at $388, with resistance at $402.
The investment outlook is positive, supported by earnings momentum, brand strength, and a 66% analyst buy rating. Risks include high valuation multiples, such as a P/E of 24.92, and sensitivity to consumer spending trends. The consensus price target of $456.50 implies 15% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
